{
    "id": 6996,
    "fullName": "VHL inact mut",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "VHL inact mut indicates that this variant results in a loss of function of the Vhl protein. However, the specific amino acid change has not been identified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 7428,
        "geneSymbol": "VHL",
        "terms": [
            "VHL",
            "HRCA1",
            "pVHL",
            "RCA1",
            "VHL1"
        ]
    },
    "variant": "inact mut",
    "createDate": "06/03/2015",
    "updateDate": "08/29/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5740,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Afinitor (everolimus) had a trend towards improved in progression free survival when stratified by the presence (median PFS=8.6 months, n=15) or absence (median PFS=5.5 months, n=16) of deleterious VHL mutations (PMID: 26951309).",
            "molecularProfile": {
                "id": 6849,
                "profileName": "VHL inact mut"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4914,
                    "pubMedId": 26951309,
                    "title": "Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26951309"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5735,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Apitolisib (GDC-0980) had no difference in progression free survival when stratified by the presence (n=5) or absence (n=17) of deleterious VHL mutations (PMID: 26951309).",
            "molecularProfile": {
                "id": 6849,
                "profileName": "VHL inact mut"
            },
            "therapy": {
                "id": 750,
                "therapyName": "GDC-0980",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4914,
                    "pubMedId": 26951309,
                    "title": "Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26951309"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8268,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PT2399 had variable impact on tumor growth in clear cell renal cell carcinoma (ccRCC) cell line and patient-derived xenograft (PDX) models with defective VHL, with decreased tumor growth in a VHL-defective ccRCC PDX model and some VHL-defective ccRCC cell line xenograft models, and no tumor suppression in other cell line xenograft models (PMID: 27595393).",
            "molecularProfile": {
                "id": 6849,
                "profileName": "VHL inact mut"
            },
            "therapy": {
                "id": 4670,
                "therapyName": "PT2399",
                "synonyms": null
            },
            "indication": {
                "id": 4467,
                "name": "clear cell renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 6586,
                    "pubMedId": 27595393,
                    "title": "On-target efficacy of a HIF-2\u03b1 antagonist in preclinical kidney cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27595393"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9339,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, VHL alterations did not impact overall survival or objective response in renal cell carcinoma patients treated with a VEGF-targeted therapy, including Avastin (bevacizumab) and Alpha 2 Interferon combination therapy, but were associated with a prolonged time to progression (PMID: 16827904).",
            "molecularProfile": {
                "id": 6849,
                "profileName": "VHL inact mut"
            },
            "therapy": {
                "id": 2511,
                "therapyName": "Alpha 2 Interferon + Bevacizumab",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7115,
                    "pubMedId": 16827904,
                    "title": "Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16827904"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8269,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TP53 R248W was associated with resistance to PT2399 in VHL-defective clear cell renal cell carcinoma cell lines in culture (PMID: 27595393).",
            "molecularProfile": {
                "id": 26217,
                "profileName": "TP53 R248W VHL inact mut"
            },
            "therapy": {
                "id": 4670,
                "therapyName": "PT2399",
                "synonyms": null
            },
            "indication": {
                "id": 4467,
                "name": "clear cell renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6586,
                    "pubMedId": 27595393,
                    "title": "On-target efficacy of a HIF-2\u03b1 antagonist in preclinical kidney cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27595393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8528,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, a clear cell renal cell carcinoma patient harboring a VHL mutation, with a tumorgraft that had demonstrated Epas1 (Hif2a) expression in 70% of tumor cells and sensitivity to a Hif2a antagonist, was progression-free for greater than 11 months following treatment with PT2385 (PMID: 27595394).",
            "molecularProfile": {
                "id": 26349,
                "profileName": "EPAS1 pos VHL inact mut"
            },
            "therapy": {
                "id": 4146,
                "therapyName": "PT2385",
                "synonyms": null
            },
            "indication": {
                "id": 4467,
                "name": "clear cell renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6674,
                    "pubMedId": 27595394,
                    "title": "Targeting renal cell carcinoma with a HIF-2 antagonist.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27595394"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 6849,
            "profileName": "VHL inact mut",
            "profileTreatmentApproaches": [
                {
                    "id": 5263,
                    "name": "mTORC1 Inhibitor",
                    "profileName": "VHL inact mut"
                },
                {
                    "id": 5034,
                    "name": "VEGFR Inhibitor (Pan)",
                    "profileName": "VHL inact mut"
                },
                {
                    "id": 5033,
                    "name": "VEGFR2 Inhibitor",
                    "profileName": "VHL inact mut"
                }
            ]
        },
        {
            "id": 26217,
            "profileName": "TP53 R248W VHL inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26349,
            "profileName": "EPAS1 pos VHL inact mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}